INmune Bio is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co. has two product platforms: dominant-negative tumor necrosis factor, which utilizes dominant-negative technology and is being developed for Alzheimer's and treatment resistant depression and cancer and an out-licensing strategy for Duchenne's Muscular Dystrophy; and Natural Killer Cell Priming Platform, which utilizes a medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation. The INMB average annual return since 2019 is shown above.
The Average Annual Return on the INMB average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether INMB average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INMB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|